<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002396</url>
  </required_header>
  <id_info>
    <org_study_id>283A</org_study_id>
    <secondary_id>GS-97-901</secondary_id>
    <nct_id>NCT00002396</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Activity of 9-[2-(R)-[[Bis[[(Isopropoxycarbonyl)- Oxy]Methoxy]Phosphinoyl]Methoxy]Propyl]Adenine Fumarate (PMPA Prodrug) in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety of single and multiple doses (28 daily doses) of&#xD;
      9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate&#xD;
      (PMPA) prodrug administered orally to HIV-infected patients. To determine the&#xD;
      pharmacokinetics of single and multiple doses of PMPA prodrug when administered orally to&#xD;
      HIV-infected patients. To evaluate the anti-HIV activity of PMPA prodrug, as demonstrated by&#xD;
      increases in CD4 cell counts and decreases in HIV RNA, when administered orally as a single&#xD;
      dose and daily for 4 weeks to HIV-infected patients with CD4 cell counts of 200 or more&#xD;
      cells/mm3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blind, placebo-controlled study, a total of 60 patients are randomized to&#xD;
      receive PMPA prodrug at 1 of 5 doses or matching placebo tablets.&#xD;
&#xD;
      Part A (Days 1-7): Patients receive a single dose of PMPA prodrug or matching placebo tablets&#xD;
      administered orally followed by a 1-week observation period. Patients who complete Part A&#xD;
      without a dose-limiting toxicity begin Part B.&#xD;
&#xD;
      Part B (Days 8-35): Patients receive either PMPA prodrug or matching placebo tablets&#xD;
      administered orally qd for 4 weeks at the same dosage level administered in Part A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection, as indicated by seropositivity for HIV infection (ELISA and Western&#xD;
             blot), positive HIV culture, or positive plasma HIV RNA.&#xD;
&#xD;
          -  CD4 cell count of 200 or more cells/mm3 within 28 days prior to study entry.&#xD;
&#xD;
          -  Plasma HIV RNA of 10,000 or more copies/ml within 28 days of study entry.&#xD;
&#xD;
          -  Minimum life expectancy of 12 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active, serious infections (other than HIV infection) that require parenteral&#xD;
             antibiotic therapy. Patients should be considered recovered if at least 2 weeks have&#xD;
             elapsed following the cessation of parenteral antibiotic therapy before enrollment.&#xD;
&#xD;
          -  Active clinically significant medical problems including cardiac disease (e.g.,&#xD;
             symptoms of ischemia, congestive heart failure, or arrhythmia).&#xD;
&#xD;
          -  Positive test for Hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
          -  Malignancy other than basal cell carcinoma or cutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Adefovir dipivoxil (bis-POM PMEA) for more than 14 days.&#xD;
&#xD;
        Within 2 weeks prior to entry:&#xD;
&#xD;
          -  Antiretroviral therapy, including nucleoside analogues, nonnucleoside reverse&#xD;
             transcriptase inhibitors, protease inhibitors, or investigational antiretroviral&#xD;
             agents.&#xD;
&#xD;
          -  Interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside&#xD;
             antibiotics, amphotericin B, cidofovir, diuretics, foscarnet, ganciclovir,&#xD;
             itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin,&#xD;
             rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic&#xD;
             corticosteroids, other agents with significant nephrotoxic potential, other agents&#xD;
             that may inhibit or compete for elimination via active renal tubular secretion (e.g.,&#xD;
             probenecid), and other investigational agents.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active drug or alcohol abuse as demonstrated by a positive screening test for drugs of&#xD;
        abuse (except marijuana or drugs used for medical indications) or substance abuse&#xD;
        considered sufficient to hinder patient compliance.&#xD;
&#xD;
        Patients who are receiving:&#xD;
&#xD;
          -  Antiretroviral therapy, including nucleoside analogues, nonnucleoside reverse&#xD;
             transcriptase inhibitors, protease inhibitors, or investigational antiretroviral&#xD;
             agents. NOTE:&#xD;
&#xD;
          -  Antiretroviral therapy may be started after completion of the Day 49 follow-up visit&#xD;
             (i.e., not earlier than 14 days after completion of dosing).&#xD;
&#xD;
          -  Interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside&#xD;
             antibiotics, amphotericin B, cidofovir, diuretics, foscarnet, ganciclovir,&#xD;
             itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin,&#xD;
             rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic&#xD;
             corticosteroids, other agents with significant nephrotoxic potential, other agents&#xD;
             with significant nephrotoxic potential, other agents that may inhibit or compete for&#xD;
             elimination via active renal tubular secretion (e.g., probenecid), and other&#xD;
             investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington / AIDS Clinical Trial Unit</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Adenine</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

